Otsuka Holdings Co Ltd
TSE:4578
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5 184
9 611
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Otsuka Holdings Co Ltd
Otsuka Holdings Co Ltd
Non-Reccuring Items
Otsuka Holdings Co Ltd
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Non-Reccuring Items
-¥235.1B
|
CAGR 3-Years
-239%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-42%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Non-Reccuring Items
-¥96.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Non-Reccuring Items
-¥53.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Otsuka Holdings Co Ltd
Glance View
Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being. For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.
See Also
What is Otsuka Holdings Co Ltd's Non-Reccuring Items?
Non-Reccuring Items
-235.1B
JPY
Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Non-Reccuring Items amounts to -235.1B JPY.
What is Otsuka Holdings Co Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 10Y
-42%
Over the last year, the Non-Reccuring Items growth was -246%. The average annual Non-Reccuring Items growth rates for Otsuka Holdings Co Ltd have been -239% over the past three years , and -42% over the past ten years .
You don't have any saved screeners yet
